Inventor · disambiguated record
Alexander Haas
Also filed as: HAAS ALEXANDER
12 granted patents·8 pending applications·50 citations·filing 2010–2024
89Inventor score
Top patents by PatentIndex Score
20 records- 0195US11286300B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2016·Granted Mar 29, 2022·11 cites·8 claims
- 0287US8907069B2Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agentBRINKMANN ULRICH·Filed 2010·Granted Dec 9, 2014·7 cites·17 claims
- 0386US9303076B2Cell-penetrating peptides and uses thereofHOFFMANN LA ROCHE·Filed 2015·Granted Apr 5, 2016·7 cites·12 claims
- 0486US9303075B2Cell-penetrating peptides and uses thereofHOFFMANN LA ROCHE·Filed 2012·Granted Apr 5, 2016·10 cites·29 claims
- 0584US9879095B2Bispecific antibodies comprising a disulfide stabilized-Fv fragmentHOFFMANN LA ROCHE·Filed 2013·Granted Jan 30, 2018·5 cites·19 claims
- 0682US9050375B2Bi-specific digoxigenin binding antibodiesBRAMLAGE BIRGIT·Filed 2010·Granted Jun 9, 2015·6 cites·17 claims
- 0782US2025376523A1Humanized anti-human cd19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2024·Application pending·0 cites
- 0878US10517945B2Covalently linked antigen-antibody conjugatesHOFFMANN LA ROCHE·Filed 2014·Granted Dec 31, 2019·3 cites·16 claims
- 0976US12215152B2Humanized anti-human CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2022·Granted Feb 4, 2025·0 cites·8 claims
- 1073US12227594B2Bispecific 2+1 contorsbodiesHOFFMANN LA ROCHE·Filed 2018·Granted Feb 18, 2025·1 cites·14 claims
- 1167US9574016B2Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agentHOFFMANN LA ROCHE·Filed 2014·Granted Feb 21, 2017·0 cites·8 claims
- 1266US12023378B2Covalently linked antigen-antibody conjugatesHOFFMANN LA ROCHE·Filed 2019·Granted Jul 2, 2024·0 cites·21 claims
- 1363US12378315B2Anti-rabbit CD19 antibodies and methods of useHOFFMANN LA ROCHE·Filed 2021·Granted Aug 5, 2025·0 cites·15 claims
- 1459US2024082437A1Split antibodies which bind to cancer cells and target radionuclides to said cellsHOFFMANN LA ROCHE·Filed 2022·Application pending·0 cites
- 1559US2021403924A1Method for selecting cells based on CRISPR/Cas-mediated integration of a detectable tag to a target proteinHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1657US2023272116A1Antibodies which bind to cancer cells and target radionuclides to said cellsHOFFMANN LA ROCHE·Filed 2021·Application pending·0 cites
- 1754US2022389116A1Antibodies for chelated radionuclidesHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 1849US2022267463A1Antibodies which bind to cancer cells and target radionuclides to said cellsHOFFMANN LA ROCHE·Filed 2020·Application pending·0 cites
- 1945US2022031871A1Antibodies for chelated radionuclides and clearing agentsHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 2044US2015166670A1Multispecific antibodiesHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alexander Haas files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →